236 related articles for article (PubMed ID: 34964270)
1. Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
Tamura T; Ninomiya K; Kubo T; Kuyama S; Tachibana S; Inoue K; Chikamori K; Kudo K; Ochi N; Harada D; Maeda Y; Kiura K
Thorac Cancer; 2022 Feb; 13(3):453-459. PubMed ID: 34964270
[TBL] [Abstract][Full Text] [Related]
2. Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study.
Harada D; Tamura T; Ninomiya K; Kubo T; Kuyama S; Tachibana S; Inoue K; Chikamori K; Kudo K; Ochi N; Maeda Y; Kiura K
Thorac Cancer; 2023 Jan; 14(3):231-236. PubMed ID: 36404396
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Gounant V; Ferré VM; Soussi G; Charpentier C; Flament H; Fidouh N; Collin G; Namour C; Assoun S; Bizot A; Brouk Z; Vicaut E; Teixeira L; Descamps D; Zalcman G
J Thorac Oncol; 2022 Feb; 17(2):239-251. PubMed ID: 34798306
[TBL] [Abstract][Full Text] [Related]
4. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
5. Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment.
Narita D; Ebina-Shibuya R; Miyauchi E; Tsukita Y; Saito R; Murakami K; Kimura N; Sugiura H
Respir Investig; 2023 Mar; 61(2):247-253. PubMed ID: 36567161
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study.
Nakashima K; Ishida M; Matsui H; Yoshida C; Nagai T; Shiraga M; Nakaoka H; Otsuka Y; Nakagama Y; Kaku N; Nitahara Y; Kido Y; Hirota Y
Hum Vaccin Immunother; 2022 Nov; 18(6):2140549. PubMed ID: 36369871
[TBL] [Abstract][Full Text] [Related]
7. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review.
Lui DTW; Lee KK; Lee CH; Lee ACH; Hung IFN; Tan KCB
Front Public Health; 2021; 9():778964. PubMed ID: 34888290
[No Abstract] [Full Text] [Related]
8. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
Olariu TR; Ursoniu S; Marincu I; Lupu MA
Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
[No Abstract] [Full Text] [Related]
9. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
11. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
12. Determinants and Effectiveness of BNT162b2 mRNA Vaccination Among Patients with Atopic Dermatitis: A Population-Based Study.
Kridin K; Schonmann Y; Onn E; Bitan DT; Weinstein O; Cohen AD
Am J Clin Dermatol; 2022 May; 23(3):385-392. PubMed ID: 35294720
[TBL] [Abstract][Full Text] [Related]
13. Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
Hibino M; Uryu K; Takeda T; Kunimatsu Y; Shiotsu S; Uchino J; Hirai S; Yamada T; Okada A; Hasegawa Y; Hiranuma O; Chihara Y; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T; Takayama K
J Thorac Oncol; 2022 Aug; 17(8):1002-1013. PubMed ID: 35752437
[TBL] [Abstract][Full Text] [Related]
14. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
Goshen-Lago T; Waldhorn I; Holland R; Szwarcwort-Cohen M; Reiner-Benaim A; Shachor-Meyouhas Y; Hussein K; Fahoum L; Baruch M; Peer A; Reiter Y; Almog R; Halberthal M; Ben-Aharon I
JAMA Oncol; 2021 Oct; 7(10):1507-1513. PubMed ID: 34236381
[TBL] [Abstract][Full Text] [Related]
15. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.
Haslak F; Gunalp A; Cebi MN; Yildiz M; Adrovic A; Sahin S; Barut K; Kasapcopur O
Int J Rheum Dis; 2022 Mar; 25(3):353-363. PubMed ID: 34978376
[TBL] [Abstract][Full Text] [Related]
16. Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study.
Piros ÉA; Cseprekál O; Görög A; Hidvégi B; Medvecz M; Szabó Z; Olajos F; Barabás E; Galajda N; Miheller P; Holló P
Dermatol Ther; 2022 May; 35(5):e15408. PubMed ID: 35218276
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine.
Lombardi A; Renisi G; Consonni D; Oggioni M; Bono P; Uceda Renteria S; Piatti A; Pesatori AC; Castaldi S; Muscatello A; Riboldi L; Ceriotti F; Gori A; Bandera A
BMC Infect Dis; 2022 Jan; 22(1):97. PubMed ID: 35090388
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients.
Ligumsky H; Safadi E; Etan T; Vaknin N; Waller M; Croll A; Nikolaevski-Berlin A; Greenberg I; Halperin T; Wasserman A; Galazan L; Arber N; Wolf I
J Natl Cancer Inst; 2022 Feb; 114(2):203-209. PubMed ID: 34453830
[TBL] [Abstract][Full Text] [Related]
19. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 and Immune-Mediated RBC Destruction.
Jacobs JW; Booth GS
Am J Clin Pathol; 2022 Jun; 157(6):844-851. PubMed ID: 34919640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
